Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 1
1954 4
1957 6
1958 3
1959 2
1961 3
1962 1
1963 1
1968 2
1977 1
1978 1
1979 1
1981 1
1984 1
1985 1
1986 1
1988 1
1993 1
1995 2
1996 3
1998 1
2000 1
2001 1
2003 2
2004 7
2005 16
2006 17
2007 12
2008 7
2009 5
2012 1
2013 3
2015 2
2016 2
2017 2
2019 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 15937151

107 results

Results by year

Filters applied: . Clear all
Page 1
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.
Valenzano KJ, Miller W, Chen Z, Shan S, Crumley G, Victory SF, Davies E, Huang JC, Allie N, Nolan SJ, Rotshteyn Y, Kyle DJ, Broglé K. Valenzano KJ, et al. J Pharmacol Exp Ther. 2004 Aug;310(2):783-92. doi: 10.1124/jpet.103.063313. Epub 2004 Mar 30. J Pharmacol Exp Ther. 2004. PMID: 15054115
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.
Whiteside GT, Harrison JE, Pearson MS, Chen Z, Fundytus ME, Rotshteyn Y, Turchin PI, Pomonis JD, Mark L, Walker K, Broglé KC. Whiteside GT, et al. J Pharmacol Exp Ther. 2004 Aug;310(2):793-9. doi: 10.1124/jpet.103.063560. Epub 2004 Mar 30. J Pharmacol Exp Ther. 2004. PMID: 15054116
Peripherally mediated antinociception of the mu-opioid receptor agonist 2-[(4,5alpha-epoxy-3-hydroxy-14beta-methoxy-17-methylmorphinan-6beta-yl)amino]acetic acid (HS-731) after subcutaneous and oral administration in rats with carrageenan-induced hindpaw inflammation.
Bileviciute-Ljungar I, Spetea M, Guo Y, Schütz J, Windisch P, Schmidhammer H. Bileviciute-Ljungar I, et al. J Pharmacol Exp Ther. 2006 Apr;317(1):220-7. doi: 10.1124/jpet.105.096032. Epub 2005 Dec 8. J Pharmacol Exp Ther. 2006. PMID: 16339394
Evidence for a selective role of the delta-opioid agonist [8R-(4bS*,8aalpha,8abeta, 12bbeta)]7,10-Dimethyl-1-methoxy-11-(2-methylpropyl)oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9H)-4,8-methanobenzofuro[3,2-e]pyrrolo[2,3-g]isoquinoline hydrochloride (SB-235863) in blocking hyperalgesia associated with inflammatory and neuropathic pain responses.
Petrillo P, Angelici O, Bingham S, Ficalora G, Garnier M, Zaratin PF, Petrone G, Pozzi O, Sbacchi M, Stean TO, Upton N, Dondio GM, Scheideler MA. Petrillo P, et al. J Pharmacol Exp Ther. 2003 Dec;307(3):1079-89. doi: 10.1124/jpet.103.055590. Epub 2003 Oct 9. J Pharmacol Exp Ther. 2003. PMID: 14551288
DAMGO and 6beta-glycine substituted 14-O-methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferens.
Al-Khrasani M, Spetea M, Friedmann T, Riba P, Király K, Schmidhammer H, Furst S. Al-Khrasani M, et al. Brain Res Bull. 2007 Oct 19;74(5):369-75. doi: 10.1016/j.brainresbull.2007.07.008. Epub 2007 Jul 30. Brain Res Bull. 2007. PMID: 17845912
107 results